1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Eli Lilly and Company

Eli Lilly and Company

1,145.60
EUR
-32.00
(-2.72%)
26.08EPS
40.58P/E
946.24BMarket Cap
Oct 29Next Earn
Eli Lilly and Company
EUROTLX:4LLY
(EuroTLX)

Recent

price

1,145.60

P/E

ratio

40.58

div

yld

0.49%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
20.87
21.8
19.72
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
89.12
Revenue per Share
4.58
3.9
3.57
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
29.88
Basic EPS, GAAP
5.13
4.97
3.72
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
15.17
Free Cash Flow per Basic Share
1.96
1.96
1.91
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.47
Dividend per Share
10.78
11.7
12.88
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
38
Book Value per Share
6.6
7.27
8.73
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
7.76
Tangible Book Value per Share
1,106
1,114
1,146
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
894
Basic Weighted Avg Shares
23,076
24,287
22,603
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
79,666
Sales/Revenue/Turnover
29.35
26.01
22.19
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
49.72
Operating Margin (%)
1,328
1,374
1,462
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,523
1,527
1,767
1,997
2,099
Depreciation Expense
5,070
4,348
4,089
4,685
2,391
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
26,711
Net Income, GAAP
22.31
18.73
24.4
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.49
Effective Tax Rate (%)
21.97
17.9
18.09
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
33.53
Profit Margin (%)
7,739
5,317
4,649
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,981
3,400
896
-1,566
4,364
20,401
16,931
Working Capital
6,771
5,465
5,519
4,200
5,333
7,972
8,368
9,941
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
47,858
LT Debt
12,413
13,536
14,774
17,641
15,388
14,590
14,081
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
33,879
Total Equity
27.93
21.98
16.85
18.89
8.69
9.11
10.48
-0.3
12.77
22.31
25.29
22.01
24.39
16.25
25.66
36.08
34.73
Return on Invested Capital (%)
29.35
22.57
20.69
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
36.53
Return on Capital (%)
46.2
33.49
28.89
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
102.44
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,635
4,000
7,050
LT Borrowings
40,868
39,370
47,858
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
895
894
892
Market Capitalization
964,714
817,484
1,081,044

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,629
54,835
64,672
Cash, Cash Equivalents & STI
7,268
5,282
8,950
Accounts Receivable, Net
17,760
18,429
20,083
Inventories
13,744
14,529
16,793
Total Current Liabilities
35,228
36,634
47,741
Payables & Accruals
22,761
22,576
27,234
ST Debt
1,635
4,000
7,050
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
7.96
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
1.73
- -
- -
- -
Similar Companies
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Merck & Company, Inc. (NYSE:MRK)
Business
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company News

Company News APIChatGPT

  • fool.com

    2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

  • gurufocus.com

    Eli Lilly Stocks Slip 1.7% Ahead of Earnings After 48% Revenue Growth

  • fxempire.com

    Eli Lilly (LLY) Price Forecast: Breakout Strengthens Ahead of Earnings

  • 247wallst.com

    UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom

  • prnewswire.com

    Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

  • fool.com

    Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

  • defenseworld.net

    449 Shares in Eli Lilly and Company $LLY Purchased by Boyd Wealth Management LLC

  • defenseworld.net

    Eli Lilly and Company $LLY Stock: Bank Pictet & Cie Europe AG Reduces Holdings

  • defenseworld.net

    Eli Lilly and Company $LLY Stock Purchased by Diversify Advisory Services LLC

  • zacks.com

    Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss

  • zacks.com

    Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

  • fool.com

    Here's What I'm Planning With My Eli Lilly Position

  • 247wallst.com

    Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher

  • fool.com

    Stock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5%

  • schaeffersresearch.com

    Dow Up 523 Points as Market Momentum Grows

  • 247wallst.com

    If Eli Lilly Grows At 10% a Year, Here's What $1,000 Becomes By 2030

  • zacks.com

    Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

  • investors.com

    Tech Stocks Rebound From Heavy Losses Before Big Earnings Reports; Apple, Lilly Eye Buy Points

  • 247wallst.com

    Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors

  • gurufocus.com

    Eli Lilly Plans Pediatric Omvoh Expansion After Phase 3 Trial Win